Feed HINDBIO.BO
HI

Hindustan Bio Sciences Limited HINDBIO.BO BSE · Healthcare · India

₹7.00 +0.00% +₹0.00

Summary

30 / 100 · Bulios Score

What speaks for it

  • Out of every 100 INR of revenue, 14 INR is left as net profit.

What to watch

  • Repaying its net debt would take 16.5 years of operating profit.
  • Revenue fell by 6.5% a year over the last 3 years.
  • The share price is above the Bulios Fair Price.
  • It earns only 5.2 INR a year on every 100 INR of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today ₹7

By our assumptions the business is worth less than its shares cost today.

P/E today 43.2
Medical - Pharmaceuticals industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 43.2 INR for 1 INR of yearly profit.

Valuation in detail

Is it growing?

It is shrinking

Revenue (INR)

Diluted EPS (INR)

Revenue fell by 6.3% a year over 5 years. Over the last 3 years it fell by 6.5% a year.

Growth in detail

Does it make money?

Reasonably

Where 100 INR of revenue goes

Net profit, industry median (Medical - Pharmaceuticals) 6.1 INR

Out of every 100 INR of revenue, 14 INR is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy